The first 60 days: Erdheim-Chester disease
Erdheim-Chester disease is a rare histiocytosis, a cancer-like overgrowth of immune cells called histiocytes that scar the long bones, the tissue around the kidneys and heart, the brain and the skin. Most cases carry the BRAF V600E mutation or another fault in the same growth pathway, and the melanoma drugs vemurafenib and cobimetinib now control the disease in most patients. Below, week by week, is what OnCo's record of Erdheim-Chester disease says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Biopsy of an accessible lesion with BRAF V600E testing and broader sequencing; FDG-PET/CT, cardiac and brain MRI, endocrine assessment.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Diagnosis, Asymptomatic bone-limited disease.
- RadiologistNamed in the standard of care for: Diagnosis, Asymptomatic bone-limited disease.
- SurgeonNamed in the standard of care for: Asymptomatic bone-limited disease.
- Medical oncologistNamed in the standard of care for: Diagnosis, BRAF V600E-mutant symptomatic disease, BRAF wild-type symptomatic disease, Second-choice or intolerant.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
- 1.Asymptomatic bone-limited diseaseConsensus recommendations for Erdheim-Chester disease (Blood 2020)
Observation with periodic PET and organ screening.
- 2.BRAF V600E-mutant symptomatic diseaseConsensus recommendations for Erdheim-Chester disease (Blood 2020)
Vemurafenib (approved 2017) or dabrafenib with trametinib; cobimetinib as an alternative; dose reduction to limit toxicity, treatment continued long term.
- 3.BRAF wild-type symptomatic diseaseConsensus recommendations for Erdheim-Chester disease (Blood 2020)
Cobimetinib (approved 2022 for histiocytic neoplasms); trametinib as an alternative MEK inhibitor.
Interferon alfa or pegylated interferon, anakinra, cladribine, methotrexate.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example BRAF V600E in tissue and plasma cell-free DNA, MAP2K1, ARAF, NRAS, KRAS, PIK3CA and kinase fusions on sequencing, CD68 and CD163 positive, CD1a and langerin negative histiocytes with Touton giant cells, FDG-PET/CT for extent and response, Cardiac MRI, brain MRI and pituitary function), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include BRAF V600E-mutant Erdheim-Chester disease, BRAF wild-type Erdheim-Chester disease with MAP2K1, ARAF, RAS or PIK3CA mutations, Erdheim-Chester disease with cardiac or central nervous system involvement.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Diagnosis
- For my situation (diagnosis), which of the standard options do you recommend and why?Guideline options include: Biopsy of an accessible lesion with BRAF V600E testing and broader sequencing; FDG-PET/CT, cardiac and brain MRI, endocrine assessment.
BRAF V600E-mutant symptomatic disease
- For my situation (braf v600e-mutant symptomatic disease), which of the standard options do you recommend and why?Guideline options include: Vemurafenib (approved 2017) or dabrafenib with trametinib; cobimetinib as an alternative; dose reduction to limit toxicity, treatment continued long term.
- Am I a candidate for Vemurafenib, Dabrafenib + trametinib, Cobimetinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
BRAF wild-type symptomatic disease
- For my situation (braf wild-type symptomatic disease), which of the standard options do you recommend and why?Guideline options include: Cobimetinib (approved 2022 for histiocytic neoplasms); trametinib as an alternative MEK inhibitor.
- Am I a candidate for Cobimetinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Second-choice or intolerant
- For my situation (second-choice or intolerant), which of the standard options do you recommend and why?Guideline options include: Interferon alfa or pegylated interferon, anakinra, cladribine, methotrexate.
- Am I a candidate for Interferon alfa-2a/2b, Cladribine, Methotrexate, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Asymptomatic bone-limited disease
- For my situation (asymptomatic bone-limited disease), which of the standard options do you recommend and why?Guideline options include: Observation with periodic PET and organ screening.
Any stage
- Are there clinical trials I could join, for example of Cobimetinib, Vemurafenib, Dabrafenib + trametinib?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Kinase inhibitors are usually needed for life and relapse follows their withdrawal”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Long-term cardiac, skin and secondary-cancer effects of indefinite BRAF and MEK inhibition are unknown”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Erdheim-Chester disease: the full pageErdheim-Chester disease is a rare histiocytosis, a cancer-like overgrowth of immune cells called histiocytes that scar the long bones, the tissue around the kidneys and heart, the brain and the skin. Most cases carry the BRAF V600E mutation or another fault in the same growth pathway, and the melanoma drugs vemurafenib and cobimetinib now control the disease in most patients.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Retroperitoneum: The space at the back of the abdomen, behind the gut's lining, holding the kidneys, adrenals, pancreas, aorta and the para-aortic lymph nodes.
- BRAF V600E mutation: A single spelling change in the BRAF gene that jams a growth switch permanently on.
- Driver mutation: One of the few mutations in a tumour that actually causes it to grow.
- Circulating tumour DNA (ctDNA): Circulating tumour DNA (ctDNA) consists of fragments of DNA shed by tumour cells into the blood, detectable with sensitive sequencing.
Every term links to the glossary.